Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary

May 12, 2026

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 51 min

Earnings Call Speaker Segments

Jost Reinhard

executive
#1

Afternoon, everyone, and good morning as well — thanks for joining the call where we'll present the first-quarter 2026 results. Today's remarks will stay tightly focused. Bill is going to talk about how the overall business performed and give an update on progress against our strategic priorities, while Wolfgang will offer more insight into the Q1 financials, the geopolitical situation as it stands right now, and what we see for the outlook. After that we'll move into the Q&A session, and the presidents of our three divisions will be there alongside Bill and Wolfgang to take your questions. Before we start, please take note of the cautionary language contained in our Safe Harbor statement. With that said, Bill, the floor is yours.

Bill Anderson

executive
#2

Thanks, Jost. Hello, everyone. It's great to be here with you today. Two months ago, we laid out our plan for 2026, and this afternoon we're reporting that our businesses are performing in line with our expectations. I'll begin by walking through the group numbers, and then give some color on each of the businesses. At the group level, we posted sales of €13.4 billion, which is 4% up on a currency and portfolio adjusted basis — and we'll be referring to that basis throughout today's call. Core EPS came in at €2.71. That's also up from where we were last year at this time. Our free cash flow in the first quarter is at negative €2.3 billion, and that's in line with our outlook, since a significant portion of our litigation-related payments fell in the first quarter. Moving on to our businesses. In Crop Science, sales grew nearly 7% year over year. This result was bolstered by roughly €450 million in additional soy licensing resolution revenue, as we communicated last quarter. Excluding this impact, our core business grew 1.4%, driven by strong growth in corn, offsetting declines we expected in crop protection. EBITDA was up, with our margin coming in around 40%. Of course, the additional licensing resolution revenue helped.

Bill Anderson

executive
#3

We additionally achieved underlying improvements through sales with better margins and through operational efficiency. In Pharma, sales came in approximately level. Nubeqa and Kerendia carried on their momentum, offsetting reductions in Xarelto and Eylea. Our EBITDA margin was 29.2%. Divestment incomes had a positive effect on this figure, which landed behind last year because of pricing pressures and launch investments. Last, Consumer Health posted 5% growth, with contributions from nearly every category. Dermatology and nutritionals reached the double digits, and nutritionals gained from our expanding e-commerce business. At 22.6%, our EBITDA margin is a bit below 2025. All in all, we are happy with the way our businesses began the year, and we are well placed to confirm our 2026 outlook. That said, it is early. We recognize that our surroundings are volatile, and we will need to remain vigilant. Our attention is on reaching our targets and delivering for farmers, patients, and consumers. Moving to our strategic priorities. The first 4 months of 2026 have been busy, and some significant weeks lie ahead. The highlights are shown on the slide. I will begin with litigation, since we are at a pivotal stage in our containment efforts. We keep advancing the class settlement agreement that we announced with leading plaintiffs' firms in February.

Bill Anderson

executive
#4

The settlement has cleared a number of obstacles. Looking at the milestones ahead, objections and opt-outs must be filed by June 4th, and the court has set the final approval hearing for July. Also, 2 weeks ago, the US Supreme Court heard our argument about why preemption is not only essential for American agriculture but also consistent with the law. We're grateful the justices took up our case and engaged seriously with the legal theory we presented. We believe our arguments were well represented. It's now up to the court to interpret the law and issue a ruling. We'll be prepared for every outcome. Our multi-pronged strategy is ongoing. We keep advocating for regulatory clarity for American farmers, and we've seen both progress and setbacks on this front, including legislation passing in Kentucky and a setback in the Farm Bill discussion. Why does this matter? What's at stake here goes beyond scoring political points. Americans want a food system that is safe, bountiful, and sustainable. They want agriculture that keeps food affordable while limiting chemical inputs to only what's necessary, and that also preserves biodiversity. Farmers, especially in times like these when farm economics are stretched, want new safe tools that secure their harvests.

Bill Anderson

executive
#5

A year ago, Bayer launched Plenexos, a novel insecticide that safeguards yields by eliminating the insects that ruin crops while protecting pollinators. It can be applied with precision, removing pests at doses as small as a few grams per acre. When I say low dose, here's what I mean: picture a soybean field the size of an American football field. You could treat it using roughly 11 grams of Plenexos's active ingredient. I've got a prop with me. These are American quarters, alright? George Washington is on the front, and these little guys, these two are worth about 50 cents, but the weight of these two quarters — that's how much Plenexos it would take to treat a football field. This is what people are looking for. They want agriculture that's greener, healthier, and more productive, and Plenexos is exactly the kind of innovation we need. It's already being applied in South America, and we want to bring it to US farmers as soon as possible. They want it, too. There's a really big thing standing in its way: a system that gives trial lawyers the authority to undermine years of regulatory and scientific scrutiny. Why introduce new products — products that cost decades and billions of dollars to research and develop — if even after a rigorous approval process, you're subject to billions of dollars in legal costs?

Bill Anderson

executive
#6

That's something we'll need to keep asking about as we move forward. Beyond the litigation area, we're continuing to deliver on every one of our priorities. Look at Pharma growth and the pipeline, for instance. I noted earlier that Kerendia is posting robust revenue gains, powered by momentum in treating patients who have chronic kidney disease and type 2 diabetes, and also in heart failure. On top of that, we've shared data in chronic kidney disease with type 1 diabetes, and one month ago — just last month — we reported positive top-line results in treating non-diabetic patients with kidney disease. So once it wins approval in these added indications, Kerendia could potentially help patients in heart failure as well as across a broad spectrum of chronic kidney disease, including in areas where few alternative options exist today. That's a strong illustration of how we aren't merely extending the reach of our medicines — we're broadening the pool of people they can serve. We also just announced a deal to acquire Profusa Therapeutics and their first-in-class development medicine in glaucoma and diabetic retinopathy, which complements very nicely the footprint and expertise we've already established in ophthalmology. We're continuing to push our plan forward, and we're dialed in on delivering our commitments in 2026.

Bill Anderson

executive
#7

At this point I'd like to pass things over to Wolfgang, who will take you through our figures. Today marks the final time he'll be doing this for Bayer. Wolfgang, the floor is yours.

Wolfgang Nickl

executive
#8

Thank you, Bill, and a very warm welcome from me as well. As Bill mentioned, this is the final occasion on which I present our quarterly results to you before I pass the baton to Judith in June. Before we get into the business, I want to sincerely thank all of you for the constructive discussions we've had over the past 8 years. It has been an eventful period, turbulent at times, but I have always valued our close exchange. I am deeply grateful to my team and to the people I've had the chance to work with across Bayer, and I am very confident that we are setting the company up for a great deal of success in the future. Let's now turn to the group results for the first quarter. Q1 net sales rose 4% compared with the prior-year quarter, driven by Crop Science and Consumer Health, while Pharma was in line with the prior year. EBITDA before special items came in at €4.5 billion, which is 9% or about €370 million above the prior-year quarter, led by a higher Crop Science result. Profits in our Pharma division declined, and EBITDA before special items for Consumer Health and Recon came in at almost the same level as in the prior year. Across divisions, we experienced the anticipated significant FX headwinds in the first quarter, totaling about €890 million to our top line and about €320 million to the bottom line.

Wolfgang Nickl

executive
#9

This time, the US dollar was the main driver behind those effects. Core earnings per share reached €2.71. Versus the prior year, that's an increase of 31 cents, or 13%, and it's largely due to roughly 40 cents of licensing resolution income plus 10 cents from tail-end divestment income in Pharma. Foreign exchange headwinds of about 20 cents more than offset these expected non-recurring effects. Free cash flow was -€2.3 billion, which is €800 million below the prior-year quarter. As expected, that came from material payouts tied to the previously announced settlement activities for PCB and also glyphosate, totaling roughly €2 billion in Q1. Operational cash contributions improved by around €1.2 billion, including the licensing resolution payments and Avelox divestment income. Net financial debt rose to €32.5 billion since year-end '25 because of the negative cash flow. Compared with a year ago, net financial debt declined by roughly €1.7 billion. Now let's look more closely at how the divisions performed. At Crop Science, the team is concentrating on executing our 5-year framework, building resilience and improving margins. Q1 net sales were €7.6 billion, +7% versus the prior year. The core business was up 9%, led by an 18% gain in seeds and traits.

Wolfgang Nickl

executive
#10

Corn was up 7%, with growth across every region. We saw strong volume gains in EMEA and LATAM, and in North America we noted higher volumes at the start of the season; the timing of sales and anticipated lower acreage are expected to bring sales down year over year in the coming quarter. Soybean sales showed a very significant increase stemming from the licensing resolution we noted. Outside of that effect, higher prices from the recovery of the dicamba label in the US and strong volumes in Latin America produced a 9% sales increase for the quarter. With the Brazil soybean transition and our continued focus on US margins, we expect these Q1 benefits to moderate as the year goes on. Purchase delays in cotton and declines in vegetable seeds were nearly offset by growth in canola. The core crop protection business fell 7% on an anticipated soft start to the season amid continued generic pressure and challenged farmer profitability. We expect partial volume recovery in Q2, led by North America and supported by Stratex herbicide growth, with the rest of the recovery focused on Latin America in the second half of the year. Glyphosate sales declined by 15% on lower volumes due to delayed purchases. Our focus is on recovery in North America in the second quarter and in Latin America in the second half of the year.

Wolfgang Nickl

executive
#11

We’re keeping a close eye on recent movements in market prices and will make strategic adjustments to our pricing in response. Turning to profitability, EBITDA before special items reached €3 billion, an 18% increase versus the prior year, producing a margin of 39.9%. That improved margin largely reflects the higher-margin sales and the soy licensing resolution, together with disciplined execution of cost savings. Those efforts offset FX headwinds of roughly 80 basis points. Moving to our Pharma business, we continue to see strong growth from our launch assets, which is balancing the anticipated declines in Xarelto and also Eylea. For Q1, that led to net sales of €4.2 billion, level with the prior year. Nubeqa grew by 57% across regions, while Kerendia sales rose by 84%, driven mainly by the US and also China. Combined, they contributed €1 billion in net sales in the first quarter. We’re also pleased with the uptake of our two new launch assets, Beyfortus and Lynparza. Beyfortus is now launched and reimbursed in 18 European countries. Lynparza has been brought to market in Germany and Switzerland as of April 1st and shows good early uptake signals following the first launch in the US at the end of last year.

Wolfgang Nickl

executive
#12

As we anticipated, Xarelto kept falling during the first quarter. Loss-of-exclusivity effects in various markets produced the expected 40% sales decrease versus a year earlier. With Eylea, we posted a 21% drop relative to Q1 of last year. We are still seeing encouraging volume gains for Eylea 8 mg, which now accounts for 46% of the Eylea franchise, yet competitive entry by biosimilars keeps weighing on us, particularly where pricing is concerned. Our base business was down 1%, since ongoing radiology growth was outweighed by weaker results elsewhere in the portfolio — chiefly softer demand in women's health plus volume-based pricing effects on Cardioaspirin and Stivarga in China. At the bottom line, EBITDA before special items fell 8% to €1.2 billion, giving a margin of 29.2%, a touch below the previous year. As expected, we feel the effects of sustained pricing pressure even as we keep investing gross into launches and innovation. Savings, healthy volume uptake, and proceeds from two smaller tail-end divestments of roughly €120 million offset this. Moving now to Consumer Health, we are concentrating on sustainable growth while managing the soft consumer sentiment we anticipate in our two largest markets.

Wolfgang Nickl

executive
#13

With that as context, net sales rose 5% during the first quarter. That growth came from a better-balanced blend of volume and price, supported by targeted spending behind our power couples and by bringing Nutrasana into the fold — the nutritionals e-commerce operation that we purchased. Nearly every category posted growth, with dermatology and nutritionals out in front, powered by innovation and robust e-commerce traction. Among the seasonal categories, cough and cold fell off because the season was milder across North America and portions of EMEA. Digestive health results took a hit from continued pharmacy consolidation in China and an ongoing shift of the channel toward e-commerce. That produced structural cutbacks in the retail inventory that customers require. We also observed certain customer orders pulled forward into the first quarter, most notably in nutritionals and allergy. Those timing effects shaped how the quarter looked, yet they leave the underlying demand outlook unchanged and are entirely captured in the assumptions behind our full-year guidance. Our EBITDA margin before special items came in at 22.6%, which shows solid underlying profitability inside our full-year guidance corridor, albeit a touch under last year. FX headwinds thinned margins by 70 basis points. Productivity gains stemming from our new operating model and active cost management, along with divestment gains on some tail-end products, gave us added financial flexibility.

Wolfgang Nickl

executive
#14

That let us increase spending behind our brands and portfolio priorities in support of growth. Now let's turn to the outlook for our divisions. Given the Q1 results, we remain on track to deliver full-year guidance at constant currencies for every one of our businesses. For the remaining quarters, let me point out just a few items. In Crop Science, the licensing resolution income has a different distribution this year, having been realized in Q1 rather than in Q4 last year. For the second quarter overall, we anticipate top- and bottom-line results at constant currencies to be broadly stable versus a year ago. After a strong Q1, corn and soy sales are expected to moderate, declining against the prior year. Growth in cotton, a partial volume recovery in glyphosate and core CP, and Stratex growth in North America should largely offset that. In Pharmaceuticals, we are firmly on track to deliver our full-year outlook. As guided, top-line growth in the second half should come in stronger than in the first half, while on margins, we expect gross investments behind launches and pipeline to increase in the quarters ahead.

Wolfgang Nickl

executive
#15

When it comes to Consumer Health, conditions in our two largest markets—the US and China—are still difficult. In the US, things got tougher during the first quarter, and we now expect a decline across the whole year. Thanks to a strong start to the year, we're still confident we can hit our full-year guidance there too. Turning to the group, we're reiterating our constant-currency outlook for the full year '26, and we'll keep watching geopolitical developments and moves in foreign exchange rates. On geopolitics, our latest assessments suggest we can absorb any potential effects inside the guidance ranges we've given for '26. We're continuing to track the situation closely as it evolves, especially in these areas: in Crop Science, we anticipate certain direct effects on sales plus added costs—above all for fuel, transportation, and energy—and these are manageable this year. That said, we're keeping a close eye on climbing energy prices and structural inflation throughout petrochemical supply chains. The resulting increases in production costs will mostly sit in inventory, so higher COGS will hit the P&L in later periods. The timing and duration of these variables could also indirectly affect acreage mix, farmer profitability, and the shifting crop protection landscape. For example, favorable PRC prices could create glyphosate pricing opportunities if conditions stay supportive.

Wolfgang Nickl

executive
#16

Broadly speaking, it's tougher to foresee how these knock-on effects will eventually play out and shape the final choices on planting and purchasing. Within our Pharma business, we don't anticipate any significant tariff impact on this year's outlook, since they would only take effect at the end of September and ought to remain at 15% under the EU-US trade deal, and we're watching the most recent developments on this closely. We'll keep applying measures to mitigate tariffs as well. Regarding drug pricing globally and MFN specifically, we're continuing to watch how things develop and to review our pricing and launch strategies. In Consumer Health, persistent geopolitical tensions might mainly hit our business through consumer sentiment and demand, while elevated oil prices could likewise influence supply and production costs. After our most recent assessment and sustained emphasis on controlling costs, we expect to remain within our '26 guidance range. Lastly on FX, consistent with how we usually operate, we've refreshed our FX estimates using month-end rates from March. Relative to constant currencies, that produces the effect displayed in the final column of slide 12. That said, this is merely a point-in-time analysis, and we would still anticipate continued volatility in foreign exchange rate developments through the rest of the year.

Wolfgang Nickl

executive
#17

To give you a sense of this, we also examined the FX effect using 5-month forward rates as of April. If we apply those rates, we'd land at a net sales headwind of roughly €1 billion, an EBITDA before special items headwind of approximately €400 million, and a core EPS headwind of about 30 cents, which aligns more closely with what we estimated previously. So with that, I'll pass it back to you, Jost, to run the Q&A.

Jost Reinhard

executive
#18

Thanks, Wolfgang. Thanks, Bill. We’ll begin the Q&A now. Before we do, a few quick housekeeping notes: if you’d like to ask something, please raise your hand and follow the directions given on the call. So that as many people as possible can take part, please keep it to two questions. First up today are Sachin Jain from Bank of America and James Quigley from Goldman Sachs. Sachin, please go ahead. Sachin, are you able to hear us?

Sachin Jain

analyst
#19

Yes, I can. Are you able to hear me?

Jost Reinhard

executive
#20

We’re hearing you at this point.

Sachin Jain

analyst
#21

Apologies for that. I just wanted to start by thanking Wolfgang for his support over the years and wishing him the best going forward. If I may, two questions about litigation. The first concerns the opt-in, opt-out. I'm just wondering whether you can give us your perspective on what visibility you have into the rates in the weeks ahead of the June 4th date, and how you think you'll be able to communicate whether it's been successful or not between the June 4th and July 9th fairness hearing? Then the second question is your perspective as a company on the oral hearing. Investors saw it as mixed. Obviously the stock was down that day. I'm just interested in your thoughts and how it will impact the opt-in, opt-out rate from your perspective. Thank you.

Bill Anderson

executive
#22

Hi Sachin. Let's see here. On visibility ahead of June 4th — yeah, we do have a limited amount of knowledge, but there is, sort of, an administrator for the class who is the official recipient of the opt-outs, and we would expect to receive some kind of update from that administrator roughly a week following the June 4th opt-out deadline. After that, I think we will definitely spend some time evaluating what that information shows. What we are looking for, as we have said previously, is an opt-out rate that is essentially zero. We have to see — depending on which opt-outs come in, and what the strengths or the merits of their cases are with respect to, I don't know, whatever the fact set of those cases happens to be — and that, I would anticipate, will take some weeks. The bottom line is that nobody should be holding their breath on June 5th, because there won't be any information coming from the company, yeah, for at least some weeks after that. Then, yeah, regarding the oral hearing — I was there 2 weeks ago yesterday, and we felt like we had a good opportunity to present our case. The US Supreme Court is not — they are not hearing about a question of whether our product caused someone's illness.

Bill Anderson

executive
#23

They are, they’re really zeroing in on matters involving how the Constitution gets read or how statutes get read. Here, the statute at issue happens to be preemption. I think, yeah, we came away feeling confident about being able to lay out those arguments. I’m not going to dig into what makes our position strong or what makes theirs strong, but I do believe one core idea deserves emphasis: FIFRA laid out clear preemption rules, and absent those rules, you honestly get regulatory chaos across the United States — at least when it comes to pesticides. Our view is that the court ought to decide this in our favor, since the case we’ve put forward is quite persuasive.

Jost Reinhard

executive
#24

Thanks, Bill. Next in the queue is James Quigley with Goldman Sachs, and after him comes Richard Vosser from JPMorgan. James, the floor is yours.

James Quigley

analyst
#25

Thanks a lot. I appreciate it, Jost, and thank you for the questions. I’d like to wish Wolfgang all the best going forward too. I have a couple of questions of my own. First, on Kerendia, which posted another strong beat this quarter. When we look at the slide in the appendix, the year-over-year sequential growth in the US appears to have slowed. Is that simply seasonality? Is it mostly related to FX? Could you discuss the relative growth you’re seeing across the approved indications in the US and China? And maybe a quick one for Rodrigo on Crop as well. You mentioned that some volumes in the Crop Protection business were shifted out into the second quarter, and that we might see a partial recovery in glyphosate and perhaps a recovery in some of the other Crop Protection products. How confident are you that this volume will come back? What visibility do you have into farmer inventories, and how much visibility do you have into possible price movements in glyphosate, given that it was quite a tailwind a few years ago? Thank you.

Bill Anderson

executive
#26

Hi James. Thank you for the question, and thank you as well for joining us and for liking Kerendia more and more, since we keep surpassing expectations. I believe there is nothing to worry about in the US. We are observing sustained robust demand. Sure, at times we are now comparing against some strong months or quarters, but I have no concerns whatsoever. We will keep rolling out additional indications now. Having it in a non-diabetic population is giving us a further boost in the renal patient group. I think the product's halo is growing month by month, and we are seeing greater confidence among prescribers. We are continuing to broaden our prescriber base, nothing to be concerned about in the US or in China on Kerendia, expect continued strength there.

Rodrigo Santos

executive
#27

James, I'll take the Crop Science question now. We're pleased to report Q1 and, as you heard from Bill and Wolfgang, to confirm guidance for the full year. That's consistent with what we had planned. In Crop Protection in particular, this too is very much in line with the plan. At this moment we are right on track executing our 5-year framework, and for Crop Protection there's a strong emphasis on it, as we laid out 1 year ago, on May 13, in the 5-year framework presentation. We're trimming the portfolio. We're carrying out some divestments, and we do expect, particularly in Q1, a moderate top line for Crop Protection, which was part of the plan, along with some regulatory effects as well. On your question about Q2, the key item is Stratex, the new dicamba formulation. We secured the approval, we handled the orders and the production, and this will have an impact especially in Q2. In the latter half of the year, we expect more growth in the Southern Hemisphere, particularly Latin America, with the launches we have such as those Bill mentioned — Plenexos, or the Fox family, Supra, Gavintru, our new herbicide too.

Rodrigo Santos

executive
#28

We’ve got additional launches and growth lined up for the second half of the year. So with that, I’ll just reiterate that we’re tracking in line with this year’s guidance, and we’re carrying out our plans the way we have been. On glyphosate specifically, at the start of the year there was a decline in PRC—at the beginning of the year, purchases from farmers paused while they waited to see what would happen. Now the direction is the reverse, as you’ve also heard. We feel confident about the volume phasing you have for Q2, Q3, and Q4. There’s a dedicated team, a separate team, handling glyphosate—very lean and very effective—and we’re responding to the opportunities in front of us, such as pricing as Wolfgang mentioned, or other opportunities we have here. With this team, we’re watching very closely how best to run this business so we can capture any opportunity that may persist across the next three quarters we have. Thank you very much.

James Quigley

analyst
#29

I appreciate that.

Jost Reinhard

executive
#30

Okay, thanks. Next up after Richard Vosser of JPMorgan, we have Laurent Favre from BNP Paribas. Richard, you're up next — go ahead, please.

Richard Vosser

analyst
#31

Thanks, Jost. I hope you're able to hear me clearly. I have a couple of questions, please. The first is on Crop Science, regarding corn. You saw strong performance, perhaps better than expected in Q1. Could you discuss your expectations for the remainder of the North America season, both on price and on volume? We can see acreage declining, but it didn't appear to have as much of an effect. How should we think about that? Then a question on Pharma, please. On the launch of Lynparza, if we could dig into that, Stefan, please. Prescriptions in the US seem to be broadly in line with the Veozah launch. How is that going? What's the reception like? What does the ramp look like from here? That would be great. Thanks very much.

Rodrigo Santos

executive
#32

Richard, on the first part of your question about Crop Science, I'll start there. You've got it exactly right. Following 2025, we're extremely pleased — we saw excellent results in seeds and traits, and Q1 was also a very solid showing in seeds and traits, even without counting the licensing resolution. The seeds and traits business is up 7%, and that matches the 7% you saw for corn. On the US specifically, you're correct. We had 98 million acres last year. At first, projections pointed to a sizable decline. We'll likely see less of a drop than that. The most recent USDA report puts it at somewhere between 94 and 95 million acres, and we should know more in the coming weeks, given commodity prices and fertilizer costs. Farmers will decide how much corn ultimately gets planted in the US. It will probably be below last year, as you said, but not as low as the initial thinking. That's what was weighing on Q2, which Wolfgang also mentioned. Overall, soybean is also at 9% even excluding the licensing. I'd just like to remind everyone that part of this licensing resolution should also have an impact on '26, but even without counting those, you've got 9% growth in soybean as well.

Rodrigo Santos

executive
#33

Seeds and traits did really well, and we're hoping to carry that momentum into the coming quarters too. With that, over to Stefan?

Stefan Oelrich

executive
#34

Thank you, Rodrigo. Richard, hello, and thank you for asking about Lynparza. I realize I probably sound like a broken record here, but we are still in the early stages. I want to be careful about getting ahead of myself and projecting too far ahead, yet the uptake has pleased us. It matches what we had anticipated. What remains important is building awareness and expanding the NKT class around our distinctive double mechanism of action. That, I believe, is what differentiates us, and prescribing physicians are increasingly acknowledging it — the evidence being that the breadth of our prescriber base is genuinely growing. Roughly 500 physicians per week are being added as new Lynparza prescribers. This does not come through very clearly in the audits, since a substantial portion of that use also happens through samples. We are making progress. As I mentioned, it is still early days. What more is there to say? Let me think. Regarding access, naturally, that is the second point. We are aiming to broaden access. How this plays out in the US: a few months in, we are now roughly a third of the way through, and we are adding accounts each month. Progress is slow, as we expected, but what we are seeing pleases us.

Jost Reinhard

executive
#35

Great. Next up after Laurent Favre of BNP Paribas is Alec Ebeling from UBS. Laurent, go ahead.

Laurent Favre

analyst
#36

Thanks, Jost, and good afternoon, everyone. I have two questions, both for Rodrigo. First, on soy: did I understand Wolfgang correctly that you expect a year-on-year sales decline in soy for Q2? That surprised me a bit, since I figure soy acreage should be up roughly 4%, and I had assumed you'd be picking up share this year thanks to the dicamba registration. Was the whole story the pull-forward into Q1, and are you now assuming only limited share gains across the whole of H1? That's my first question. The second is a broader one about inflation and what we're seeing in the supply chain in India and China: are you seeing less pressure, and do you expect less pressure from the generic companies given all the issues, particularly around petrochemical availability down there? Thank you.

Rodrigo Santos

executive
#37

Thank you, Laurent. I'll begin with your second question, Laurent. Right now, there's a great deal of uncertainty in the market. When you consider the whole Middle East war, how long it will go on, and what that means for energy costs and, ultimately, for pricing? You are already seeing some reaction in generic pricing at the moment. Over the short term, there may be some pricing opportunities you could seize here. Also, I think you simply need to bear in mind that this likewise affects next season, since the higher cost is also hitting production and will hit the inventory of products we'll be selling next year, and we'll discuss that one later. For this year, as far as glyphosate goes, and we're monitoring this, as you'd expect, every week, we might have a chance to capture some opportunities we'll be looking for — not just in glyphosate, but in some other crop protection products too. You're right. Potentially, over the short term, there could be some opportunities there, and we're watching very closely.

Rodrigo Santos

executive
#38

Regarding soybean, there was 9% growth in the first quarter if you exclude the licensing resolution. We do anticipate that this year will mark the start of the recovery we're going to see for soybean. We're quite enthusiastic about what we're doing at present. I met with the team yesterday, and we went back over the launch plans for Viconic in the US, and we'll have the chance to show that in September in Iowa, where our innovation event will take place and all of you are invited. I hope you can be there, because we're as excited about bringing Viconic to US farmers in the coming seasons as we are about Preceon and the other launches we have. On soybean specifically this year, we got off to a great start. We don't foresee a major impact in Q2, no, but we need to watch what happens in LATAM during the second part of the year, right? We're making progress with our Intacta 2 Xtend, which is above 30% penetration at the moment, while our competitor's launch there sits under 10%. We're also excited about developing the new technology in LATAM.

Rodrigo Santos

executive
#39

We're also getting ready for the upcoming launches of Intacta 5+, which is likewise arriving over the coming years. This year, soybean is making a comeback. We're noticing some of the pricing movement you brought up. There's the new herbicide that's being launched, but a great deal of groundwork is going into soybean as we intend to win back substantial share in the US across '27, '28, '29, and past that. There's some prep work and real enthusiasm for the seasons ahead too. Thank you.

Laurent Favre

analyst
#40

Thanks.

Jost Reinhard

executive
#41

Excellent. After Alec Ebeling of UBS comes Christian Faitz of Kepler Cheuvreux. Alec, go ahead.

Alec Ebeling

analyst
#42

Hi there, and thanks for taking my questions. I have two, please. First, on Crop and when a possible Middle East effect might show up. Given that most US farmers may already have their fertilizer for the season, would any potential impact be expected in the first half? And then, in the second half, what potential impact could the conflict in the Middle East have? Have you quantified that impact, and are there any active mitigation steps you can take? Second, on Pharma, specifically pharma tariffs. You've noted no expected impact from pharma tariffs this year. To avoid potential tariffs, much like some of your competitors, are you engaging in discussions with the US administration? Thank you.

Rodrigo Santos

executive
#43

Alec, thank you for that question. Let me begin with Crop Science. You've got it exactly right, correct? In the US, the effect falls more on the final planting season, right? This is a good illustration of what I referenced regarding USDA stating, "Well, you may have 94, 95 million acres of corn," and that figure could move between 96 and 93 million acres of corn, just as an example, because of what you just described. It comes down to how farmers react to the fertilizers, depending on whether they can secure the final piece of that equation, and whether they can shift a little more toward soybean or not. In the US, you've got it exactly right. It impacts more the closing of the season, the closing of planting on the farmers' side, and the swing they can make here. The bulk of the season is complete. The key question, depending on how long the war in the Middle East lasts, concerns the second half of the year and the impact on the Southern Hemisphere, right? Particularly regarding fertilizer costs and the farmers' economics. We're going to keep watching that one. We're also working closely with our teams to mitigate. We're putting our plans in place to mitigate any major risks we have.

Rodrigo Santos

executive
#44

A solid illustration of what I just mentioned is the work we’ve been doing across seeds and traits, along with our new CP launches, to help offset part of that. There’s a lot of uncertainty surrounding the Middle East. We’ll be monitoring it very closely and will share more with you in the quarters ahead as well. Stefan?

Stefan Oelrich

executive
#45

Appreciate that, Rodrigo. On the tariff question — yes, we are in fact factoring tariffs into the guidance for this year, so that's fully reflected there. As for next year, it's a bit early to say, though we're looking at every option available and speaking with quite a few people. Keep watching, and you'll be hearing more on that front.

Jost Reinhard

executive
#46

Great. Following Christian at Kepler, Charles Pitman-King from Barclays and Rajesh Kumar from HSBC will speak. Christian, you're up next. Please go ahead.

Christian Faitz

analyst
#47

Yes. Good afternoon and good day, and Wolfgang, all the best for your post-Bayer time. Actually, two questions about two small activities. In Consumer Health, where operating performance was pretty stable, why did operating cash flow fall by more than 25% in the quarter? Was there any special reason beyond working capital? On veggy seeds, I noticed that veggy seeds sales were down quite heavily. I assume that part of this is due to the Middle East situation per March. If my assumption is true, i.e., the Middle East situation, should we count on even bigger decline for the second quarter?

Bill Anderson

executive
#48

Okay, so — Wolfgang or Julio, who wants to take on the topic of cash flow in Consumer Health?

Wolfgang Nickl

executive
#49

Christian, Wolfgang here. There’s nothing concerning in Consumer Health. It’s simply that Q1 of last year was exceptional for us. As you’ll recall, we generated over a billion in free operating cash flow in that segment. For the full year, we anticipated somewhat less, purely due to the timing of certain working capital items and somewhat higher investments in that area. Yes, we are slightly lower year over year, but it’s not a major issue. Cash flow is shaping up very well for us here too.

Christian Faitz

analyst
#50

Appreciate it.

Rodrigo Santos

executive
#51

Regarding your Crop Science question, you've got it exactly right. The effect on vegetables hit the Middle East—not just Iran, but our other countries there too. Our team is pursuing logistics solutions to make up for it during Q2 and Q3. Beyond that, we aren't anticipating anything more this year. Once again, with the Middle East war, we'll have to watch how things develop. What we experienced in Q1 with vegetables specifically stemmed from the Middle East war and how it affected our sales in that region. Once more, the team is pursuing alternative logistics routes for Q2 and Q3 to claw back part of that. Naturally, the Iran piece in particular is a minor share of it and will probably be a full-year hit, yet it remains a minor, non-material share for the Crop Science division across the full year. Thank you so much.

Christian Faitz

analyst
#52

Thank you both so much. That was really useful.

Jost Reinhard

executive
#53

Great. Next in the queue is Charles Pitman-King from Barclays, and after him we’ll hear from Rajesh, then we’ll wrap up the call. Charles, the floor is yours.

Charles Pitman-King

analyst
#54

Hi, everyone. Thank you very much for taking my questions. The first one is for me, and it returns to the litigation topic — I would be curious about any additional details you can share regarding how the opt-out rate is progressing. I note that the Bayer briefing documents dated the 21st of April indicated that 60% of Roundup claims are still represented under the class action across roughly 12 law firms. I am wondering whether, over the past 3 weeks or so, you have observed any shift in those conversations that could bring us up to date on that figure, whether following the SCOTUS hearing or Judge Chhabria's comments on the 30th of April. Then, secondly, on your ophthalmology franchise: noting that Eylea 8 mg now accounts for 46% of Bayer Eylea sales, I am wondering how such a swift increase in share might potentially alter your outlook for Eylea beyond '26. I am just thinking about this Profusa Therapeutics acquisition — with a view to preserving your SG&A relationships within the ophthalmology section, as we wait for the Phase 3 trial results, how do you expect to bridge and sustain those relationships during that period? Thank you.

Bill Anderson

executive
#55

Thanks, Charles. On the opt-out rate, I honestly don’t have much to add, since those are essentially choices the law firms need to make together with their clients. We don’t insert ourselves into that process. There isn’t much else to cover there. We did clear a few obstacles. There were objections and similar matters, but they got resolved, and yes, from what we can tell, the class program remains on schedule.

Stefan Oelrich

executive
#56

Thank you. Regarding ophthalmology, let's begin with Eylea and then move to what you refer to as the bridging. So 8 mg now accounts for roughly half of our sales, which is a positive, but regrettably the total franchise is in fact where we told you it would be — we're in the -20s, and we anticipate that will persist. The reasoning is that 8 mg will take over, and we anticipate some ongoing Eylea revenue from that despite the fact that we keep enduring substantial pricing pressure here across the board. Profusa, the acquisition, should be viewed not merely as a commercial endeavor but also as something through which we apply our expertise in this area. When I mention expertise, I mean both on the scientific front and with our KOL network, and in hopefully being truly adept at establishing a solid and swift late-stage clinical development program for this new medicine. Kindly also keep in mind that we lack a commercial infrastructure for ophthalmology in the US — much of it must be built. Naturally, from what we will still have for Eylea, contingent on how quickly we can bring this across the finish line, and there remain a few risks along the way for the Profusa asset, we will attempt to bridge as much as we can, but don't view this purely as a commercial bridge play.

Charles Pitman-King

analyst
#57

I really appreciate it.

Jost Reinhard

executive
#58

Great. Rajesh Kumar from HSBC has the final questions for us today. Rajesh, the floor is yours.

Rajesh Kumar

analyst
#59

Good afternoon, and thanks for taking my questions. My first one is for Bill. I appreciate that you're putting capital to work in M&A. News on the class action and the Supreme Court will likely arrive at roughly the same time, and then we probably get a fairness hearing. Clarity on the balance sheet, though, probably only shows up much later in the year. Given that we still don't know how the litigation's balance sheet impact might develop, what strategic choices are you making on capital allocation? Any background on how you're approaching that problem would be much appreciated. My second question concerns Crop Science. Predicting the second- and third-order impacts is a very hard problem to crack. Mechanically, if you could help us understand that — say feed prices are rising, for what period are your input costs hedged? How long does it take you to raise prices and pass them through? The mechanics, or the clockwork, behind how that filters into your P&L and cash flows would be much appreciated. Great.

Bill Anderson

executive
#60

Thank you, Rajesh. On capital allocation, the main source of funds, I'd say, is operating income—and over the coming few years we intend to grow that operating income substantially. This company ought to be able to produce far more cash than it has been producing. That's partly why we like the class structure, since we've largely placed the big chunk of cost behind us and can move ahead. We've established a system—our dynamic shared ownership system—that operates on 90-day cycles, with every team across the company striving to deliver improvements each 90 days. We're seeing ongoing improvements, cost reductions, and abundant additional growth opportunities across all three divisions. Make no mistake, we definitely plan to invest in our future in R&D across all three divisions, but operating income should be the primary source of funds. We managed that before, and we will manage it going forward. We're having further discussions about what we want to do regarding the Pharma pipeline, Crop Science opportunities, and OTC switches in Consumer Health.

Bill Anderson

executive
#61

These are items we’re seeing that we can mostly cover through the plans we already have in place. I’ll now turn it over to Rodrigo.

Rodrigo Santos

executive
#62

Rajesh, thanks for that. Let me take your specific question on Crop Protection. Most of what we sell in 2026 was made in 2025, given the lead time. At the end of the day, the raw material and energy cost effects we see today flow through into production of the crop protection products we'll sell next year. On the dynamics you asked about, that's partly the lead time in Crop Protection. You'll see more of that impact. We'll discuss '27 later in the season. Again, how long the war lasts and what the impact is—we'll need to watch that this year. Let me use this to reframe things. When we planned '26, we planned '26 following the performance of '25, having confirmed the performance of '25 as another step in the direction we're taking under the 5-year framework. We're pleased to be taking another step forward in that direction, and we're working hard, including in Crop Protection, to grow our margin.

Rodrigo Santos

executive
#63

Q1 came in right at that same level, and for this year overall we expect an EBITDA margin of 20% to 22% across the whole business. That represents most of what the team is focused on at the moment. We feel confident about delivering '26, and with the 5-year framework we'll build out all the plans we have for '27 and beyond. Thanks for giving me the chance to speak to that in response to the question.

Bill Anderson

executive
#64

With that said, I'll hand it over to you.

Wolfgang Nickl

executive
#65

Rajesh, likely regarding the second part, on the way we hedge this. Clearly, we don't just do currency hedging—we're also hedging things like corn and soy prices for our input, what we have to pay growers. We hedge energy too, to the extent it's economically viable. And then, of course, in this environment we have a major focus on hedging currencies. Just as a reminder, translational risks aren't hedged by us, but we hedge all booked transactional risks plus a good chunk of anticipated transactional risks. I think we're pretty state-of-the-art in that area and do whatever we can to buffer volatility.

Rajesh Kumar

analyst
#66

Thanks.

Bill Anderson

executive
#67

Alright, I'll wrap things up for today. On behalf of the Board of Management, I'd like to offer a few remarks about Wolfgang, and I know I'm also speaking for plenty of investors who came to know him during his time at Bayer and before that. When I got here 3 years ago, Wolfgang was roughly 5 years into his tenure. Spending 8 years at Bayer, from 2018 to 2026, isn't a walk in the park — that's a phrase Wolfgang always enjoys, so I'll borrow it here. In my experience, he has always had a firm grasp of what's happening, aware of the details while never losing sight of the larger picture. Everyone on the management board benefits greatly from the support he provides — the kind you need when circumstances are stressful. Calm under pressure, lucid in his thinking, and simply a wonderful person and a friend. I suspect we haven't heard the last from Wolfgang, but we're glad for him as he moves into the next chapter of his life. All the best to you, Wolfgang. Yeah. So

Wolfgang Nickl

executive
#68

Thanks a lot.

Bill Anderson

executive
#69

I appreciate everyone taking the time to be with us on this call today.

Jost Reinhard

executive
#70

Thanks, Bill. I suppose this is the final earnings call for Wolfgang. We will certainly miss you, Wolfgang. I hope everyone has a wonderful day. Many thanks.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.